Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Drug Manufacturers - Specialty & Generic

Healthcare
$28.96 +1.17%

+$0.51 today

Market cap
$6.02B
Beta
0.54
P/E (TTM)
-87.6
EPS (TTM)
-$0.50
52W Low $30.83High $59.68

Volume 2.71M

Average 0.64M

SUPN Operating Cash Flow

Cash generated by the company's core business operations during the period.

Supernus Pharmaceuticals, Inc.NASDAQ: SUPN

Operating Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Operating cash flow turns negative

Q2 FY2026 operating cash flow was -$4.81M, compared with $58.54M a year earlier. Trailing-twelve-month operating cash flow was $19.91M. Over 3 fiscal years it compounded at -26.0% a year.

Context

  • Operating cash flow amounted to 6.6% of revenue in FY2025, down 19.4 pp from a year earlier.
  • Operating cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly operating cash flow holds near -$4.81M or moves back toward the trailing-twelve-month quarterly average of $4.98M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$4.81M-107.2% QoQ
Last fiscal yearDec 2025
$47.33M-72.5% YoY
LTMJun 2026
$19.91M-89.4% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-108.2%——
1 year-72.5%——
3-year CAGR-26.0%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
47.33M USD
Year-over-year change
-72.5%
4-year CAGR
-21.9%

Operating Cash Flow vs competitors

How SUPN compares with its peers on the latest reported figures

  • SUPN's LTM Jun 2026 operating cash flow of $19.91M is the smallest of the 3 companies compared; the peer median is $287.01M.
  • Its year-over-year change of -89.4% is the lowest of 3, against a peer median of +5.9%.
  • Operating cash flow amounts to 2.4% of revenue for SUPN, versus a peer median of 27.7%.
SUPN Competitors Peer median
Operating Cash Flow for SUPN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$331.04M +66.8%+38.4%41.6%
ALKSAlkermes plcLTM Sep 2026$242.99M -55.1%+191.4%13.9%
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026$19.91M -89.4%-26.0%2.4%
Peer median (excluding SUPN) $287.01M+5.9%+114.9%27.7%

Competitors are the stored peer set for SUPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income53.42M60.71M1.32M73.87M(38.55M)
Depreciation & Amortization32.6M85.54M84.86M80.41M91.56M
Deferred Income Tax(4.99M)(26.32M)(25.71M)(20.14M)5.21M
Stock-Based Compensation17.91M17.57M26.76M27.76M33.05M
Change in Working Capital3.57M(24.24M)(9.14M)(2.05M)(75.16M)
Accounts Receivables3.87M(16.37M)18.77M2.08M(22.3M)
Inventory(14.58M)(17.86M)6.11M15.81M(7.5M)
Accounts Payables18.18M(19.16M)(36.29M)(15.02M)(24.57M)
Other Working Capital(3.9M)29.14M2.28M(4.92M)(20.79M)
Other Non-Cash Items24.62M3.57M33M12.11M31.22M
Operating Cash Flow127.13M116.83M111.09M171.95M47.33M
Capital Expenditures(2.05M)(412K)(551K)(725K)(1.34M)
Acquisitions (Net)(311.69M)(14K)00(293.09M)
Purchases of Investments(311.57M)(406.99M)(101.62M)(688.01M)(475.94M)
Sales of Investments530.51M190.74M370.9M498.86M774.92M
Other Investing Activities12.89M14K09K(439K)
Investing Cash Flow(81.91M)(216.66M)268.73M(189.87M)4.11M
Debt Repayment(137.52M)0(402.5M)00
Common Stock Issued7.1M12.42M6.61M14.91M37.62M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(22.9M)(1.99M)(2.72M)(28.49M)
Financing Cash Flow(130.42M)(10.48M)(397.88M)12.19M9.13M
Effect of Forex Changes00000
Net Change in Cash(85.21M)(110.31M)(18.07M)(5.72M)60.57M
Free Cash Flow125.08M116.41M110.53M171.23M45.99M

Supernus Pharmaceuticals, Inc.

NASDAQ:SUPN

Intrinsic Alpha fair value

Locked

Current Price

$28.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.